





“Over the next two years, please indicate the degree to which your organization will increase or decrease its...” (n=260)


## Investment in AI for clinical trials (n=246)



## Use of adaptive trial designs (n=253)




## Focus on enrolling a demographically diverse population (n=254)






"Over the next two years, please indicate the degree to which your organization will increase or decrease its..." (n=260)


## Use of sites outside the US and/or Western Europe for patient recruitment for Phase I/II/III clinical trials (n=254)



## Use of digital biomarkers in clinical trials (n=241)



## Use of wearable sensors / connected health devices in clinical trials (n=233)




Source:  
Phase I and Phase II/III CRO Benchmarking (17th Ed.)  
ISR Market Research, 2025.




"Over the next two years, please indicate the degree to which your organization will increase or decrease its..." (n=260)

## Implementation of systems/platforms to decrease the burden of CRO management (n=252)



## Use of functional service provider (FSP) resources from CROs (n=242)



## Need for cryopreservation services during clinical trials (n=214)

